Pharnext SA — the French biopharmaceutical company developing PXT3003 as a therapeutic candidate to…
Iqra Mumal, MSc
Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Iqra Mumal, MSc
Researchers have found that two proteins, Sox2 and Id2, play a protective role in preventing further damage in specialized nervous…
ACE-083, an investigative therapy for the treatment of Charcot-Marie-Tooth (CMT) disease, was well tolerated and resulted in increased…
The proteins NME3 and CSNK1G3 can help increase production of proteins lacking in genetic diseases with an underlying nonsense mutation…
Researchers have found that low levels of ceramide, a lipid molecule, leads to changes in mitochondrial structure and function, resulting…
A lot of people with Charcot-Marie-Tooth (CMT) disease have surgery to correct foot deformities, a British study reports. Another important…
Researchers have identified MCM3APÂ as a gene involved in the development of a childhood-onset version of the neurological disorder Charcot-Marie-Tooth disease.